Frédéric Lavielle

  • Citations Per Year
Learn More
UNLABELLED (131)I treatment in thyroid cancer patients may induce side effects, including extrathyroidal cancer and leukemia. There are still some uncertainties concerning parameters that may influence the effective half-life of (131)I and the absorbed doses by extrathyroidal organs. METHODS Whole-body retention of radioiodine was measured in 254(More)
BACKGROUND Thyroid cancer patients treated with radioiodine are potential source of radiation exposure for other individuals. Thus, we evaluated the radiation dose received by family members of thyroid cancer patients treated with (131)I after hospital discharge. MATERIALS AND METHODS Seventy-six family members of 56 thyroid cancer patients were included(More)
Purpose. – The aim of the present study was to quantitatively assess the performance of a block matching-based automatic registration algorithm integrated within the commercial treatment planning system designated ISOgrayTM from Dosisoft. The accuracy of the process was evaluated by a phantom study on computed tomography (CT), magnetic resonance (MR) and(More)
PURPOSE The aim of the present study was to quantitatively assess the performance of a block matching-based automatic registration algorithm integrated within the commercial treatment planning system designated ISOgray from Dosisoft. The accuracy of the process was evaluated by a phantom study on computed tomography (CT), magnetic resonance (MR) and(More)
PURPOSE Radioimmunotherapy with anti-CD20 antibodies (Abs) labeled with beta-emitters is now used in the treatment of non-Hodgkin's lymphoma (NHL). Because (90)Y is a pure beta-emitter, no direct image of its distribution can be obtained in humans. In this paper, we present in this study imaging data of (90)Y-Ab distribution in human-mantle-cell lymphoma(More)
  • 1